AGA Family of Websites:
AGA Journals
AGA Journals
AGA University
AGA University
AGA University
AGA Research Foundation
AGA University
AGA Community
AGA University
AGA Job Board
Biosimilars: How to Make the Switch
  February 16, 2021

New webinar series on biosimilars starting Feb. 24

Join Drs. Christina Ha, Raymond Cross and Fernando Velayos for the first of four panels in the series Biosimilars: How to Make the Switch.
Share on facebook
Share on twitter
Share on linkedin
Share on email

AGA is proud to introduce its latest course offering, Biosimilars: How to Make the Switch, developed in partnership with Medical Minds and supported by an educational grant from Pfizer, Inc. 

This four-part series will focus on real-world practical approaches to the adoption of biosimilars and the data demonstrating the safety and efficacy of biosimilars in different clinical settings. You will also learn how to integrate biosimilars into your clinical setting and address any patient concerns about switching therapies. Each activity is free and certified for a maximum of 0.5 AMA PRA Category 1 Credits™, 2.0 total.

The first webinar takes place virtually on Feb. 24, at 8 p.m. EST. Esteemed panelists Christina Ha, MD, FACG, AGAF, Raymond Cross, MD, MS, AGAF, and Fernando Velayos, MD, MPH, AGAF, will review what we know today about biosimilars and the clinical evidence supporting biosimilars, including:

  • Definition of a biosimilar.
  • Development and approval process for biosimilars.
  • Recent publications from the U.S. and Europe with an emphasis on clinical data in new starts with biosimilars versus originator biologics.
  • Switching between originator biologics and biosimilars in inflammatory bowel disease.
  • Interchangeability, therapeutic drug monitoring, and immunogenicity.

Watch for the remaining three webinars coming soon:

  • Part Two: How to achieve seamless adoption of biosimilars into your practice.
  • Part Three: Integration of the patient perspective through shared decision making and patient counseling.
  • Part Four: Case studies demonstrating successful transition to a biosimilar. When and when not to switch to a biosimilar.

To learn more and register, visit AGA University

Your hub for GI education is
AGA University
Discussion Icon

Discuss this news

Share this article in the AGA Community, your member-only platform for sharing your thoughts and ideas with your colleagues.

Not a member? Join AGA.

By using this site, you agree to our updated Privacy Policy.